Trials / Conditions / Cancer of Unknown Primary Site

Cancer of Unknown Primary Site

15 registered clinical trials studyying Cancer of Unknown Primary Site — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	18F-FAPI PET in Cancers of Unknown Primary Site NCT07372963	First Affiliated Hospital of Zhejiang University	—
Not Yet Recruiting	The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP) NCT07366008	Haukeland University Hospital	N/A
Completed	Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary NCT05841966	Rigshospitalet, Denmark	N/A
Unknown	FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary NCT05263700	Peter MacCallum Cancer Centre, Australia	N/A
Completed	Sintilimab in Cancer of Unknown Primary NCT05024968	M.D. Anderson Cancer Center	Phase 2
Unknown	Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China NCT04952103	Fudan University	—
Completed	Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid Biomarkers NCT04750109	The Christie NHS Foundation Trust	—
Recruiting	TCF-001 TRACK (Target Rare Cancer Knowledge) Study NCT04504604	TargetCancer Foundation	N/A
Active Not Recruiting	Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers NCT04459273	Jonsson Comprehensive Cancer Center	Phase 1
Unknown	Nivolumab/Ipilimumab in Second Line CUP-syndrome NCT04131621	University Hospital Heidelberg	Phase 2
Completed	Trial of Pembrolizumab in Cancer of Unknown Primary NCT03752333	Imperial College London	Phase 2
Completed	A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Vers NCT03498521	Hoffmann-La Roche	Phase 2
Completed	Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary NCT03278600	Fudan University	Phase 3
Completed	APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors NCT03053466	Apollomics (Australia) Pty. Ltd.	Phase 1
Completed	Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine NCT01845337	University of Edinburgh	Phase 2